PEN - Penumbra Medical Sales Growth YoY (Last 12 Months)

Innovative systems for combating blood clots have become the global benchmark for saving patients, with Penumbra, Inc. (PEN) leveraging continuous R&D cycles and a consumables sales model for growth. A monopoly status within the niche guarantees high margins and an increase in free cash flow. The 12-month year-over-year revenue change history clearly demonstrates this trend, where 16.80 represents the latest level value.
Summary analytical data breakdowns for Penumbra (PEN)

Professional capital evaluates Penumbra, Inc. (PEN) through the lens of its ability to generate organic cash flow amid intense pressure from Medtronic and Stryker. By analyzing the year-over-year revenue growth trend on a rolling basis, the investor tracks sales dynamics over the last 12 months, allowing for the timely detection of stagnating catheter demand or the impact of FDA regulatory restrictions on the asset's liquidity.